Metabolic_Liver_Injury

Published: 9 October 2024| Version 1 | DOI: 10.17632/tg3wbfb63x.1
Contributor:
Puneet Punnet

Description

To explore the intricate connections between metabolic factors and liver injury progression. This dataset includes key lipid-related markers such as triglycerides and lipoprotein(a) [Lp(a)], along with detailed clinical measurements of liver health indicators like gamma-glutamyl transferase (Gamma-GTP), glutamate pyruvate transaminase (GPT), and triglycerides serum levels. In addition to metabolic parameters, the dataset captures the severity of liver damage through histological features such as **lobular inflammation**, **ballooning**, and **steatosis**, classified into multiple stages. The liver injury progression is further detailed through NAS (NAFLD Activity Score) and categorized by stage to assess non-alcoholic steatohepatitis (NASH) risk. The dataset also includes drug usage data such as **statin**, **ezetimibe**, **fibrate**, and **EPA usage**, allowing researchers to investigate the effects of these medications on metabolic liver injury. Demographic variables like **gender** and **age** are included to enable the assessment of potential confounding factors. This dataset is valuable for exploring the effects of metabolic disturbances and drug interventions on liver health, aiming to contribute to the understanding of conditions like non-alcoholic fatty liver disease (NAFLD) and NASH. **Key Attributes:** - Statin_Usage, Colestilan_Usage, Ezetimibe_Usage, Fibrate_Usage, EPA_Usage - Age, Gender - Liver enzymes: GPT, Gamma-GTP - Lipid-related factors: Triglycerides_Serum, Lp(a)_mg_dL - Histological markers: Lobular_Inflammation (1-3), Ballooning (1-2), Steatosis (2-3) - Disease severity stages: NAS_Stage, Stage_Category, Group_Statin+Ezetimibe

Files

Categories

Liver Metabolic Disease Excluding Non-Alcoholic Fatty Liver Disease, Metabolic Liver Disease

Licence